ozanimod

Bristol Myers' bowel disease drug fails to meet main goal in late-stage study
Reuters
Thu, 03/28/24 - 05:07 pm
Bristol Myers Squibb
Crohn's Disease
clinical trials
ozanimod
BMS Flying High in May With Opdivo, Zeposia FDA Approvals
BioSpace
Fri, 05/28/21 - 11:23 am
Bristol Myers Squibb
FDA
clinical trials
Opdivo
Zeposia
ozanimod
ulcerative colitis
BMS' Recently Approved MS Drug Shows Promise in Ulcerative Colitis Study
BioSpace
Tue, 06/2/20 - 11:20 pm
Bristol-Myers Squibb
Zeposia
ozanimod
ulcerative colitis
Just in time to assure a decision before CVR deadline, Bristol Myers Squibb files NDA for Celgene/bluebird CAR-T
Endpoints
Tue, 03/31/20 - 10:47 am
Bristol-Meyers Squibb
CAR-T
Celgene
ide-cel
Bluebird Bio
liso-cel
ozanimod
FDA Approves Bristol Myers MS Drug, But Pandemic Will Delay Launch
Xconomy
Thu, 03/26/20 - 10:42 am
Bristol-Meyers Squibb
Celgene
M&A
ozanimod
MS
mutliple sclerosis
drug launches
FDA
COVID-19
Zeposia
Go or no go? Covid-19 upstages US regulatory decisions
EP Vantage
Tue, 03/24/20 - 10:30 am
FDA
regulatory
Bristol-Myers Squibb
ozanimod
Esteve
E-58425
Fabre-Kramer
AstraZeneca
Imfinzi
Astellas
Vesicare
AbbVie
Neurocrine
Orlissa
Sanofi
MenQuadfi
opicapone
Acceleron
Reblozyl
Janssen files MS pill, ahead of FDA decision on BMS’ rival
Pharmaforum
Thu, 03/19/20 - 11:06 am
Janssen
JNJ
multiple sclerosis
MS
FDA
ponesimod
Bristol-Myers Squibb
ozanimod
10 Drugs Expected to Enter the Market This Year Could be Blockbusters, Analysis Says
BioSpace
Mon, 03/9/20 - 11:10 pm
biosimilars
Amgen
Allergan
Roche
Rituxan
Bristol-Myers Squibb
ozanimod
risdiplam
Biomarin
valrox
A Big Month Ahead for the FDA and Bristol-Myers Squibb
Motley Fool
Sat, 02/22/20 - 11:39 pm
Bristol-Myers Squibb
Celgene
FDA
ozanimod
Opdivo
Reblozyl
Blockbusters in waiting: drug launches to watch in 2020
Pharmaforum
Mon, 02/17/20 - 11:33 pm
drug launches
Biohaven
rimegepant
Novartis
ofatumumab
Celgene
ozanimod
Akebia Therapeutics
vadadustat
Biomarin
valrox
Gilead Sciences
filgotinib
Novo Nordisk
oral semaglutide
inclisiran
Immunomedics
sacituzumab govitecan
AstraZeneca
Enhertu
Bristol-Myers Squibb
liso-cel
Bristol-Myers confident of approvals linked to higher Celgene investor payout: Bristol executive
Reuters
Sat, 01/11/20 - 12:06 am
Bristol-Myers Squibb
Celgene
M&A
liso-cel
ozanimod
bb2121
FDA
BMS investors bet big on 3 newly acquired Celgene drugs for cancer and MS
Fierce Pharma
Sun, 11/24/19 - 11:35 pm
Bristol-Myers Squibb
Celgene
M&A
ozanimod
liso-cel
bb2121
Lift off! Celgene MS effort launches hot air balloon to highlight brain health
Fierce Pharma
Mon, 08/5/19 - 11:14 am
Celgene
multiple sclerosis
MS
ozanimod
drug marketing
3 Drugs Under FDA Review With Blockbuster Potential
Motley Fool
Fri, 06/21/19 - 11:24 am
AbbVie
Upadacitinib
rheumatoid arthritis
Novartis
brolucizumab
wet age-related macular degeneration
Celgene
ozanimod
relapsing multiple sclerosis
Celgene can breathe a sigh of relief as FDA accepts once-spurned ozanimod application — setting a target date on a blockbuster decision
Endpoints
Thu, 06/6/19 - 09:53 am
Celgene
FDA
EMA
ozanimod
multiple sclerosis
Celgene refiles ozanimod with FDA 1 year after regulatory snafu
Fierce Biotech
Wed, 03/27/19 - 10:20 am
Celgene
ozanimod
MS
multiple sclerosis
How This Looming Patent Battle Could Challenge Bristol-Celgene Deal
Investors Business Daily
Wed, 03/13/19 - 10:13 am
Celgene
Novartis
ozanimod
MS
multiple sclerosis
patents
Bristol-Myers Squibb
M&A
Celgene Submits MS Drug for Approval in Europe, FDA Filing on Track
Xconomy
Mon, 03/11/19 - 10:25 pm
Celgene
Bristol-Myers Squibb
Europe
FDA
M&A
MS
multiple sclerosis
ozanimod
3 Potential New Drugs Held Up by the Shutdown
Motley Fool
Sat, 01/19/19 - 06:35 pm
FDA
government shutdown
Aimmune Therapeutics
AR 101
Celgene
fedratinib
Bristol-Myers Squibb
ozanimod
The 20 Hottest Pipeline Drugs to Watch in 2019
BioSpace
Sun, 01/6/19 - 02:09 pm
VX-659 + tezacaftor + ivacaftor
semaglutide
JCAR017
ARGX-113
aducanumab
elafibranor
NKTR-214
DS-8201
GSK2857916
ozanimod
SGT-001
valoctocogene roxaparvovec
voxelotor

Pages